Heart Failure | Access and Reimbursement | Chronic Heart Failure | US | 2016
The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary research from U.S. cardiologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. Understanding the interaction between payers and physicians, including the impact of reimbursement decisions on the prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in this indication.
Related Market Assessment Reports
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
